The study measured how many people had this antibody increase, to estimate the number of people infected with SARS-CoV-2. They then calculated IFR by dividing the number of COVID-19 deaths by the number of infected people.
If @stephaniemlee is correct and misleading information was used to recruit *some* members of the sample, then that should make us even less sure than the sample is randomized.
That is a non-random, unevenly-distributed means of recruiting people.
The authors state:
"The raw prevalence of antibodies in our sample was 1.5% [...]. [...] unweighted prevalence adjusted for test-performance characteristics was 1.2% [...]" academic.oup.com/ije/advance-ar…
I've been critical of the Santa Clara study, but its IFR estimate of 0.17% represents a substantial improvement over the ~0.01% estimate Bendavid + Bhattacharya gave in late March
~0.01% requires the US population be >14X larger than it actually is
There are at least 3 types of explanation for what's occurring in various southeast Asian countries:
1) insufficient testing that misses many infections and/or misses many COVID-19 deaths 2) lower number of infections 3) lower proportion of infected people die of COVID-19
3/E
For explanation 1:
It's unlikely their testing misses more deaths, since their excess deaths don't outpace their reported COVID-19 deaths more than in many 'western' countries.
Some background:
- PFR, or population fatality rate, is COVID-19 deaths per capita (i.e. per the total population)
- IFR, or infection fatality rate, is COVID-19 deaths per infected person
That makes no sense since 0.23% is Ioannidis' *global* estimate. The USA's IFR would be higher than that, since IFR increases with age and the USA is older on average
Potholer54 made a video rebutting Cummins' points, @theresphysics corrected Cummins' misrepresentation of his research, and @dr_barrett made a rebuttal thread as well:
Serology isn't missing many asymptomatic + pauci-symptomatic infections, once one adjusts for sensitivity based on calibration (long-term sensitivity is better for anti-spike vs. anti-nucleocapsid)
Also, I'll focus on studies that did representative sampling of the general population.
So no sampling just hospital patients, blood donors, healthcare workers, etc.